TIDMPRTC
PureTech Health PLC
05 September 2018
5 September 2018
PureTech Health plc
PureTech's Vedanta Biosciences Adds Susan Dillon, PhD, to Board
of Directors
Former Global Head of Immunology at Janssen brings extensive
drug development experience in immunology and infectious
disease
PureTech Health plc (LSE: PRTC) ("PureTech Health"), an advanced
biopharmaceutical company developing novel medicines for
dysfunctions of the Brain-Immune-Gut (BIG) Axis, is pleased to note
that Vedanta Biosciences today announced the appointment of Susan
Dillon, PhD, as an independent member to its Board of Directors. Dr
Dillon is a recognised leader in the field of immunology and brings
extensive drug development experience to the Vedanta Biosciences'
Board of Directors.
Dr Dillon previously served as Global Therapeutic Area Head for
Immunology at Janssen Research & Development, LLC, one of the
Janssen Pharmaceutical Companies of Johnson & Johnson. During
her 16-year tenure, Dr Dillon led biologics discovery and global
Immunology R&D teams that were responsible for achieving
numerous regulatory approvals for innovative antibody products for
autoimmune diseases that delivered combined sales in excess of $10
billion, including REMICADE(R), SIMPONI(R), STELARA(R), and most
recently TREMFYA(R), the first anti-IL-23 monoclonal antibody to be
approved. Dr Dillon is currently Co-founder, President and Chief
Executive Officer of Aro Biotherapeutics, a biotechnology company
focused on next generation protein medicines. She serves on the
Board of Directors of the Wistar Institute and is an advisor to the
DMAX Foundation which is focused on mental health.
Bharatt Chowrira, JD, PhD, President and Chief of Business and
Strategy at PureTech Health, said: "As a highly respected leader in
the field of immunology, Dr Dillon is a terrific addition to the
Vedanta Biosciences Board. We look forward to working with her and
drawing upon her wealth of experience in drug development as
Vedanta Biosciences advances their clinical pipeline of product
candidates."
The full text of the announcement from Vedanta Biosciences is as
follows:
Vedanta Biosciences Appoints Susan Dillon, PhD, to Board of
Directors
Former Global Head of Immunology at Janssen led development of
multiple innovative therapies
Cambridge, Massachusetts, September 5, 2018-Vedanta Biosciences,
a clinical stage company developing a new category of therapies for
immune-mediated and infectious diseases based on rationally defined
consortia of human microbiome-derived bacteria, today announced the
appointment of industry leader Susan Dillon, PhD, as an independent
member of its Board of Directors. Dr Dillon brings a wealth of drug
development experience in immunology and infectious disease, having
led the approvals and expansions of several blockbuster
products.
Chris Viehbacher, Chairman of Vedanta Biosciences' Board of
Directors and Managing Partner of Gurnet Point Capital said, "Dr
Dillon is a recognised leader in the field of immunology who brings
an impressive track record from her tenure at Janssen Research
& Development. We are delighted to welcome her to the Vedanta
Biosciences Board and look forward to her insights as we continue
to pioneer the microbiome field."
Dr Dillon said, "I have followed the microbiome field closely
and believe Vedanta Biosciences is building the industry's leading
platform with compelling science, impressive R&D, and
manufacturing capabilities. I am excited to be joining the Board of
Directors and I look forward to working with this exceptional
team."
Dr Dillon is Co-founder, President and Chief Executive Officer
of Aro Biotherapeutics, a biotechnology company focused on next
generation protein medicines. Prior to Aro Biotherapeutics, Dr
Dillon served as Global Therapeutic Area Head for Immunology at
Janssen Research & Development, LLC, one of the Janssen
Pharmaceutical Companies of Johnson & Johnson. During her
16-year tenure, Dr Dillon led biologics discovery and global
Immunology R&D teams that were responsible for achieving
numerous regulatory approvals for innovative antibody products for
autoimmune diseases that delivered combined sales in excess of $10
billion, including REMICADE(R), SIMPONI(R), STELARA(R), and most
recently TREMFYA(R), the first anti-IL-23 monoclonal antibody to be
approved.
Dr Dillon currently serves on the Board of Directors of the
Wistar Institute and is an advisor to the DMAX Foundation which is
focused on mental health. In 2013, she was named one of the "Top
Women in Biotech" by FierceBiotech. Dr Dillon earned her PhD in
Microbiology and Immunology from Thomas Jefferson University, and
she holds a BS and an MS in Medical Technology from State
University of New York at Buffalo and Temple University School of
Medicine, respectively.
"We are very pleased to have Sue join our Board of Directors,"
said Bernat Olle, PhD, Co-founder and Chief Executive Officer of
Vedanta Biosciences. "Sue's experience leading the development of
important immunology-focused medicines from discovery-phase to
commercialization will be invaluable as we advance our pipeline.
Sue was one of the earliest microbiome champions in the
pharmaceutical industry and understands the potential of this field
to change medicine."
About Vedanta Biosciences
Vedanta Biosciences is a clinical-stage company developing a new
category of therapies for immune-mediated and infectious diseases
based on rationally defined consortia of human microbiome-derived
bacteria. Vedanta Biosciences is a leader in the microbiome field
with capabilities and deep expertise to discover, develop, and
manufacture live bacteria drugs. These include what is believed to
be the largest collection of human microbiome-associated bacterial
strains, a suite of proprietary assays to select pharmacologically
potent strains, vast proprietary datasets from human interventional
studies, and facilities for cGMP-compliant manufacturing of
rationally-defined bacterial consortia in powder form. Vedanta
Biosciences' pioneering work, in collaboration with its scientific
co-founders, has led to the identification of human commensal
bacteria that induce a range of immune responses - including
induction of regulatory T cells, CD8+ T cells, and Th17 cells,
among others. These advances have been published in leading
peer-reviewed journals, including Science (multiple), Nature
(multiple), Cell, and Nature Immunology. Vedanta Biosciences has
harnessed these biological insights and its capabilities to
generate a pipeline of programmes in infectious disease, autoimmune
disease, allergy, and immune-oncology.
Vedanta Biosciences was founded by PureTech Health (PRTC.L). Its
scientific co-founders are world-renowned experts in immunology and
microbiology who have pioneered the fields of innate immunity,
Th17, and regulatory T cell biology, and include Dr Ruslan
Medzhitov (Yale and Howard Hughes Medical Institute (HHMI)), Dr
Brett Finlay (University of British Columbia and HHMI), Dr Kenya
Honda (inventor of Vedanta Biosciences' lead product candidate;
Keio University and RIKEN), Dr Dan Littman (New York University and
HHMI), Dr Alexander Rudensky (Sloan Kettering and HHMI), and Dr
Jeremiah Faith (Mount Sinai School of Medicine).
About PureTech Health
PureTech Health (LSE: PRTC) is an advanced biopharmaceutical
company developing novel medicines for dysfunctions of the
Brain-Immune-Gut (BIG) Axis. The Company has developed deep insight
into the connection between the individual components of these
systems and the resulting role in many chronic diseases, which
represent the majority of healthcare spend and have proven
resistant to established therapeutic approaches. By harnessing this
emerging field of human biology, PureTech Health is developing new
categories of medicines with the potential to have great impact on
people with serious diseases.
PureTech Health is advancing a rich pipeline of innovative
therapies across two divisions: the Affiliates division and the
Internal division. Its Affiliates division includes two product
candidates that are preparing for potential regulatory approval in
the United States and Europe as well as other novel clinical and
pre-clinical programmes. These affiliates are developing
ground-breaking platforms and therapeutic candidates in
collaboration with some of the world's leading experts.
PureTech's Internal division is advancing a pipeline fuelled by
recent discoveries in lymphatics and immune cell trafficking to
modulate disease in a tissue-specific manner. These programmes
leverage the transport and biodistribution of various immune system
components for the targeted treatment of diseases with major unmet
needs, including cancers, autoimmune diseases, and neuroimmune
disorders.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
Investors EU media US media
Allison Mead Talbot Ben Atwell, Rob Winder Tom Donovan
+1 617 651 3156 +44 (0) 20 3727 1000 +1 857 559 3397
amt@puretechhealth.com ben.atwell@FTIconsulting.com tom@tenbridgecommunications.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAUGURWBUPRPGC
(END) Dow Jones Newswires
September 05, 2018 02:01 ET (06:01 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024